Importantly, in in vivo experiments with TROP2-positive endometrial cancer xenografts established from a patient with a biologically aggressive tumor (i.e., mixed clear cells and G3 endometrioid histology), we were able to demonstrate that injection of Dato-DXd is highly effective in inducing regression of endometrial cancer xenografts. Here, TACSTD2 is linked to endometrial cancer.